HLB Therapeutics Co.,Ltd.
Research HLB Therapeutics Co.,Ltd. (115450.KQ) on Bullrun: market cap KRW 235.77B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker115450.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 235.77B
- Financial periodQ2 2026
- RevenueKRW 12.56B
- Net income-KRW 8.87B
- Free cash flow-KRW 5.10B
- Gross margin-10.7%
Valuation Snapshot
latest market cap is KRW 235.77B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 235.77B | n/a | n/a | n/a |
Dividend history
About HLB Therapeutics Co.,Ltd.
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is HLB Therapeutics Co.,Ltd.'s market cap?
HLB Therapeutics Co.,Ltd.'s market capitalization is KRW 235.77B.
What does HLB Therapeutics Co.,Ltd. do?
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB Therapeutics Co.,Ltd. in December 2021.